非小细胞肺癌中EGFR和EML4-ALK的最新治疗方法
EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer.
作者信息
De Mello Ramon Andrade, Liu Davi J J, Aguiar Pedro N, Tadokoro Hakaru
机构信息
Department of Biomedical Sciences and Medicine, University of Algarve, Campus de Gambelas, Ala nascente, Edifício 7, 3º Andar, 8005-139, Faro, Portugal.
出版信息
Recent Pat Anticancer Drug Discov. 2016;11(4):393-400. doi: 10.2174/1574892811666160803090944.
BACKGROUND
Non-small cell lung cancer is the leading cancer-related cause of death.
OBJECTIVE
We review the latest therapies for NSCLC with EGFR and ELM4-ALK mutations as well as the most relevant studies and promising patents.
METHOD
A literature search of PubMed database was carried out to identify recent Clinical Trials using EGFR therapies and novel patents involving diagnosis and therapies on NSCLC. We conducted a search to find new therapy strategies, new biomarkers, and selected five patents we find relevant.
RESULTS
Over the last few years, identification of cancer harboring epidermal growth factor receptor mutations (EGFR) or chromosomal rearrangements of anaplastic lymphoma kinase (ALK) led to new ways in classifying and treating NSCLC. On the other hand, acquired resistance are a constantly challenge in the management of patients with these mutations and new drugs options are in development to improve and amplify treatment strategies.
CONCLUSIONS
Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. To understand the disease molecular profile is mandatory to define the best approach for each patient.
背景
非小细胞肺癌是癌症相关死亡的主要原因。
目的
我们综述了针对具有表皮生长因子受体（EGFR）和棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶（EML4-ALK）突变的非小细胞肺癌的最新治疗方法以及最相关的研究和有前景的专利。
方法
对PubMed数据库进行文献检索，以识别近期使用EGFR疗法的临床试验以及涉及非小细胞肺癌诊断和治疗的新型专利。我们进行检索以寻找新的治疗策略、新的生物标志物，并挑选了五项我们认为相关的专利。
结果
在过去几年中，对携带表皮生长因子受体突变（EGFR）或间变性淋巴瘤激酶（ALK）染色体重排的癌症的识别为非小细胞肺癌的分类和治疗带来了新方法。另一方面，获得性耐药在这些突变患者的管理中一直是一个挑战，并且正在开发新的药物选择以改进和扩大治疗策略。
结论
目前，EGFR酪氨酸激酶抑制剂（例如：厄洛替尼、吉非替尼、奥希替尼）和ALK抑制剂（克唑替尼、色瑞替尼、阿来替尼）为晚期非小细胞肺癌的治疗带来了新面貌。了解疾病的分子特征对于为每位患者确定最佳治疗方法至关重要。
Zotero 插件